Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Although Deutsche Bank agrees with most analysts that emerging markets are an important growth driver for big pharma, the brokerage believes that many observers under appreciate the challenges ahead, and that familiar strategies such as branded generics and local acquisitions may be short-term plays that won't necessarily translate to long-term success in rapidly changing markets like Brazil, Russia, India and China
You may also be interested in...
A Busy Month: Russia Looks To Localization, Technology Transfer To Spur Innovation (Part 2 of 2)
It’s only 2012, but Russia’s Pharma 2020 program hit new highs last month with novel deals from Abbott, J&J, Merck and Pfizer.
Pfizer Joins Russia Land Rush, But Chooses To Partner Rather Than Build
Pfizer Inc. has signed a memorandum of understanding with ChemRar High Tech Center, a Moscow incubator, to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries.
Pfizer Joins Russia Land Rush, But Chooses To Partner Rather Than Build
Pfizer Inc. has signed a memorandum of understanding with ChemRar High Tech Center, a Moscow incubator, to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries.